Abstract
The aim was to evaluate Leu-M1 immunoreactivity as a prognostic factor in phaeochromocytoma. Anti-Leu-M1 monoclonal antibodies were used to determine the Leu-M1 immunoreactivity in 17 histologically confirmed phaeochromocytomas from 15 patients, using an avidin-biotin technique. Ten patients had a sporadic phaeochromocytoma, and five had multiple endocrine neoplasia type 2A (MEN 2A). Malignancy was diagnosed in three patients by the presence of metastases. Leu-M1 immunoreactivity was shown in 12 (70.5%) phaeochromocytomas. Three patterns of arrangement were observed: isolated (scattered positive cells) (n = 3); focal (aggregates of positive cells) (n = 5), and diffuse patterns (dispersed positive cells) (n = 4). Two cases of malignant phaeochromocytoma were positive (one focal and one isolated pattern). All cases of MEN 2A showed immunoreactivity, although no characteristic pattern was prevalent. A diffuse pattern was observed in all phaeochromocytomas longer than 7 cm. In conclusion, Leu-M1 expression is frequent in phaeochromocytoma. However, Leu-M1 immunoreactivity seems to be useless in predicting malignant behaviour and to be influenced mainly by tumour size.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bravo E. L. Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma. Endocr Rev. 1994 Jun;15(3):356–368. doi: 10.1210/edrv-15-3-356. [DOI] [PubMed] [Google Scholar]
- Nativ O., Grant C. S., Sheps S. G., O'Fallon J. R., Farrow G. M., van Heerden J. A., Lieber M. M. Prognostic profile for patients with pheochromocytoma derived from clinical and pathological factors and DNA ploidy pattern. J Surg Oncol. 1992 Aug;50(4):258–262. doi: 10.1002/jso.2930500413. [DOI] [PubMed] [Google Scholar]
- Nativ O., Grant C. S., Sheps S. G., O'Fallon J. R., Farrow G. M., van Heerden J. A., Lieber M. M. The clinical significance of nuclear DNA ploidy pattern in 184 patients with pheochromocytoma. Cancer. 1992 Jun 1;69(11):2683–2687. doi: 10.1002/1097-0142(19920601)69:11<2683::aid-cncr2820691110>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
- Neumann H. P., Berger D. P., Sigmund G., Blum U., Schmidt D., Parmer R. J., Volk B., Kirste G. Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N Engl J Med. 1993 Nov 18;329(21):1531–1538. doi: 10.1056/NEJM199311183292103. [DOI] [PubMed] [Google Scholar]
- Pinkus G. S., Thomas P., Said J. W. Leu-M1--a marker for Reed-Sternberg cells in Hodgkin's disease. An immunoperoxidase study of paraffin-embedded tissues. Am J Pathol. 1985 May;119(2):244–252. [PMC free article] [PubMed] [Google Scholar]
- Schröder S., Dralle H. Prognostic factors in medullary thyroid carcinomas. Horm Metab Res Suppl. 1989;21:26–28. [PubMed] [Google Scholar]
- Schröder S., Schwarz W., Rehpenning W., Löning T., Böcker W. Prognostic significance of Leu-M1 immunostaining in papillary carcinomas of the thyroid gland. Virchows Arch A Pathol Anat Histopathol. 1987;411(5):435–439. doi: 10.1007/BF00735224. [DOI] [PubMed] [Google Scholar]
- Sheibani K., Battifora H., Burke J. S., Rappaport H. Leu-M1 antigen in human neoplasms. An immunohistologic study of 400 cases. Am J Surg Pathol. 1986 Apr;10(4):227–236. doi: 10.1097/00000478-198604000-00001. [DOI] [PubMed] [Google Scholar]